Myocardial scintigraphy, echocardiography and proBNP for early detection of myocardial cardiotoxicity in breast cancer patients after chemo-radiotherapy

Hellenic Journal of Nuclear Medicine

Volumn 14, Issue 3, 2011, Pages 269-273

  Tzonevska, Antonia ^a   Tzvetkov, Krasimir ^a   Atanasova, Mariana ^a   Chakarova, Anna ^a   Piperkova, Elena ^a  

^a SHAT Oncology ^*  (Bulgaria)

Author keywords

Echocardiography; GSPET myocardial scintigraphy; ProBNP; Treatment induced cardiotoxicity

Indexed keywords

ANTHRACYCLINE; BRAIN NATRIURETIC PEPTIDE; TETROFOSMIN TC 99M; TRASTUZUMAB; BIOLOGICAL MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RADIOTHERAPY; CARDIOTOXICITY; ECHOCARDIOGRAPHY; FEMALE; GATED SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE PERFUSION; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; PERFUSION; RADIATION DETECTION; RADIATION DOSE; TREATMENT RESPONSE; BREAST TUMOR; EARLY CANCER DIAGNOSIS; HEART LEFT VENTRICLE FUNCTION; MYOCARDIAL PERFUSION IMAGING; QUALITY OF LIFE;

BIOMARKERS; BREAST NEOPLASMS; CARDIOTOXICITY; EARLY DETECTION OF CANCER; ECHOCARDIOGRAPHY; HUMANS; MYOCARDIAL PERFUSION IMAGING; NATRIURETIC PEPTIDE, BRAIN; QUALITY OF LIFE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 83255162660     PISSN: 11081430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Chanan-Khan A., Srinivasan S, Czuczman M. Prevention and management of cardiotoxicity from antineoplastic therapy. J Supp Onc 2004; 2(3): 251-67.
2. Pai VB,Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Safty 2000; 22: 263-302. (Pubitemid 30213944)
3. Shan K, Lincoff M, Young JB. Anthracycline-Induced Cardiotoxicity. Annals of Intern Med 1996; 125: 147-58.
4. Butany J, Ahn E, Luk A. Drug-related cardiac pathology. J Clin Pathol 2009; 62: 1074-84.
5. Pfeffer B, Tziros C, Katz RJ. Current Concepts of Anthracycline Cardiotoxicity: Pathogenesis, Diagnosis and Prevention. Br J Cardiol 2009; 16(2): 85-9.
6. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 1996; 273: 542-7.
7. Berry G., M. Billingham M, Alderman E et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity. Annuals of Oncology 1998; 4(9): 711-6.
8. Fisher B, Redmond C, Wickerham DL et al. Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 1989; 7: 572-82. (Pubitemid 19126792)
9. Haq MM, Legha SS, Choksi J et al. Doxorubicin-induced congestive heart failure in adults. Cancer 1985; 56: 1361-5. (Pubitemid 15230583)
10. Olson R, Mushlin P. Doxorubicin cardiotoxicity: Analysis of prevailing hypothesis. FASEB J 1990; 12(4): 3076-86.
11. Lipshultz SE, Sanders S, Colan SD et al. Monitoring for anthracycline cardiotoxicity. Pediatrics 1994; 93(3): 433-7. (Pubitemid 24067017)
12. Steinherz LJ, Steinherz PG, Tan CT et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266: 1672-7.
13. Combs AB, Acosta D. Toxic mechanisms of the heart: a review. Toxicol Pathol 1990; 4(18): 583-96.
14. Carrio I, Ertorch M, Lopez-Pousa A. Assessing anthracycline cardiotoxicity in the 1990s. Eur J Nucl Med 1996; 23(4): 359-64. (Pubitemid 26118319)
15. Larsen RL, Jakacki RI, Vetter VL et al. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 1992; 70: 73-7.
16. Tjeerdsma G, Meinardi M, Van der Graaf WTA et al. Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart 1999; 81: 419-42.
17. Stoddard MF, Seeger J, Liddell NE et al. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol 1992; 20: 62-9.
18. 111In- antimyosin in mapping anthracycline myocardial injury. Update 1995; 2(2): 44-5.
19. 123I-MIBG, Eur J Cancer 1995; 1 (31A): 26-31.
20. Miyagawa M, Tanada S, Hamamoto K. Scintigraphic evaluation of myocardial uptake of 201 thallium and technetium-99m pyrophosphate utilizing a rat model of chronic doxorubicin cardiotoxicity. Eur. J Nucl Med 1991; 18: 332-8.
21. Emily Ho E, Brown A, Barrett P et al. Subclinical anthracycline-and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiography study. Heart 2010; 96: 701-7.
22. 99mTc-MIBI. Cancer Chemother Pharmacol 1993; 2(32): 386-91.
23. Gyenes G, Fornander T, Carlens P et al. Detection of radiation-indused myocardial damage by technetium-99m sestamibi scintigraphy. EJNM 1997; 24(3): 286-92. (Pubitemid 27165857)
24. Geus-Oei L, Mavinkurve-Groothuis A, Bellerson L et al. Scintigraphic techniques for early detection of cancer treatment-indused cardiotoxicity. J Nuc Med 2011; 52(4): 560-71.
25. Bovelli D, Plataniotis G, Roila F. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical practice guidelines. Annals of Onc 2010; 21(Suppl 5): v277-v82.